Bicycle Therapeutics
BCYC
105 hedge funds and large institutions have $915M invested in Bicycle Therapeutics in 2024 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 36 increasing their positions, 32 reducing their positions, and 18 closing their positions.
40% more call options, than puts
Call options by funds: $793K | Put options by funds: $567K
14% more capital invested
Capital invested by funds: $804M → $915M (+$111M)
13% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 32
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
2% less funds holding
Funds holding: 107 → 105 (-2)
3.14% less ownership
Funds ownership: 88.27% → 85.14% (-3.1%)
11% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$21.3M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$19.4M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
+$11.5M |
| 4 |
Principal Financial Group
Des Moines,
Iowa
|
+$10.2M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
+$7.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
-$21.8M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$14.2M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$11.9M |
| 4 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$9.64M |
| 5 |
PA
Perceptive Advisors
New York
|
-$7.29M |
BCYC Hedge Fund Activity: Q3 2024 in Review
105 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Bicycle Therapeutics (BCYC) for Q3 2024, worth a combined $915M — up 14% from $804M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of BCYC and 16 opened new positions — a net loss of 2 holders — while 32 trimmed existing stakes and 36 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $21.3M. The largest seller was Fairmount Funds Management, cutting an estimated $21.8M.
- 105 institutional investors held Bicycle Therapeutics (BCYC) as of Q3 2024, down from 107 in Q2 2024.
- Funds reported $915M of Bicycle Therapeutics stock for Q3 2024, up 14% quarter-over-quarter.
- 16 funds opened new Bicycle Therapeutics positions in Q3 2024 and 18 closed out, a net change of -2 holders.
- The largest Bicycle Therapeutics buyer in Q3 2024 was T. Rowe Price Associates, an estimated $21.3M added.
- The largest Bicycle Therapeutics seller in Q3 2024 was Fairmount Funds Management, an estimated $21.8M sold.
Based on aggregated 13F filings for Q3 2024.